GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Puma Biotechnology Inc (NAS:PBYI) » Definitions » Asset Turnover

PBYI (Puma Biotechnology) Asset Turnover : 0.38 (As of Sep. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Puma Biotechnology Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Puma Biotechnology's Revenue for the three months ended in Sep. 2024 was $80.5 Mil. Puma Biotechnology's Total Assets for the quarter that ended in Sep. 2024 was $212.9 Mil. Therefore, Puma Biotechnology's Asset Turnover for the quarter that ended in Sep. 2024 was 0.38.

Asset Turnover is linked to ROE % through Du Pont Formula. Puma Biotechnology's annualized ROE % for the quarter that ended in Sep. 2024 was 135.90%. It is also linked to ROA % through Du Pont Formula. Puma Biotechnology's annualized ROA % for the quarter that ended in Sep. 2024 was 38.18%.


Puma Biotechnology Asset Turnover Historical Data

The historical data trend for Puma Biotechnology's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Puma Biotechnology Asset Turnover Chart

Puma Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.10 0.94 1.08 1.02 1.04

Puma Biotechnology Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.33 0.20 0.23 0.38

Competitive Comparison of Puma Biotechnology's Asset Turnover

For the Biotechnology subindustry, Puma Biotechnology's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Puma Biotechnology's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Puma Biotechnology's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Puma Biotechnology's Asset Turnover falls into.



Puma Biotechnology Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Puma Biotechnology's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=235.637/( (222.059+230.528)/ 2 )
=235.637/226.2935
=1.04

Puma Biotechnology's Asset Turnover for the quarter that ended in Sep. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=80.542/( (205.002+220.721)/ 2 )
=80.542/212.8615
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Puma Biotechnology  (NAS:PBYI) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Puma Biotechnology's annulized ROE % for the quarter that ended in Sep. 2024 is

ROE %**(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=81.268/59.7985
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(81.268 / 322.168)*(322.168 / 212.8615)*(212.8615/ 59.7985)
=Net Margin %*Asset Turnover*Equity Multiplier
=25.23 %*1.5135*3.5596
=ROA %*Equity Multiplier
=38.18 %*3.5596
=135.90 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Puma Biotechnology's annulized ROA % for the quarter that ended in Sep. 2024 is

ROA %(Q: Sep. 2024 )
=Net Income/Total Assets
=81.268/212.8615
=(Net Income / Revenue)*(Revenue / Total Assets)
=(81.268 / 322.168)*(322.168 / 212.8615)
=Net Margin %*Asset Turnover
=25.23 %*1.5135
=38.18 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Puma Biotechnology Asset Turnover Related Terms

Thank you for viewing the detailed overview of Puma Biotechnology's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Puma Biotechnology Business Description

Traded in Other Exchanges
N/A
Address
10880 Wilshire Boulevard, Suite 2150, Los Angeles, CA, USA, 90024
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Executives
Michael Patrick Miller director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4 L2
Maximo F Nougues officer: Chief Financial Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Jeffrey Jerome Ludwig officer: Chief Commercial Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Douglas M Hunt officer: See Remarks C/O PUMA BIOTECHNOLOGY,INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Alan H Auerbach director, 10 percent owner, officer: PRESIDENT, CEO & SECRETARY 10940 WILSHIRE BLVD. SUITE 600, LOS ANGELES CA 90024
Brian M Stuglik director C/O VERASTEM, INC., 117, NEEDHAM MA 02494
Jay M Moyes director
Adrian Senderowicz director C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Allison Dorval director C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Troy Edward Wilson director C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Alvin F Wong officer: Chief Scientific Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Alessandra Cesano director 700 BALTIC CIRCLE, SUITE 716, REDWOOD CITY CA 94065
Ann Calby Miller director C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Richard Paul Bryce officer: SR VP, CLINICAL RESEARCH & DEV C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Hugh O'dowd director C/O NEON THERAPEUTICS, INC., 40 ERRIE STREET SUITE 110, CAMBRIDGE MA 02139